{"id":450437,"date":"2021-03-04T07:03:47","date_gmt":"2021-03-04T12:03:47","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450437"},"modified":"2021-03-04T07:03:47","modified_gmt":"2021-03-04T12:03:47","slug":"hutchison-china-meditech-limited-reports-2020-full-year-results-and-provides-business-updates-and-evolves-corporate-identity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchison-china-meditech-limited-reports-2020-full-year-results-and-provides-business-updates-and-evolves-corporate-identity\/","title":{"rendered":"Hutchison China MediTech Limited Reports\u00a02020\u00a0Full Year Results and Provides Business\u00a0Updates and Evolves Corporate Identity"},"content":{"rendered":"

\nCompany to Host Annual Results Call & Webcast Today at 1 p.m. GMT \/ 8 a.m. EST \/ 9 p.m. HKT
\n<\/h2>\n
\n

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2021 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (\u201cHUTCHMED<\/a>\u201d) (Nasdaq\/AIM: HCM), an innovation-driven, commercial-stage biopharmaceutical company, today reports its audited financial results for the year ended December 31, 2020 and provides updates on key clinical and commercial developments.\u00a0\u00a0 The Company also intends to seek shareholders\u2019 approval to change its name to HUTCHMED (China) Limited at its forthcoming Annual General Meeting. For more information on the new corporate name, see 2020 Full Year Results & Business Updates\u2014VI.\u00a0Evolution of Our Corporate Identity<\/em>.<\/p>\n

\n 2020 FULL YEAR RESULTS & BUSINESS UPDATES<\/strong>\n <\/p>\n

\u201cAt the heart of HUTCHMED lies a prolific in-house novel drug discovery and development engine that has produced ten clinical-stage drug candidates and a further seven late-stage preclinical assets in oncology and immunology over the past fifteen years.\u201d said Mr. Simon To, Chairman of HUTCHMED. \u201cOur aim is to bring these internally discovered and developed innovations to patients the world-over.\u201d<\/p>\n

\u201cTo support this strategic objective, we have built an oncology and immunology operation with around 1,200 personnel based mainly in our two core markets, China and the U.S. In China, supported by a robust manufacturing infrastructure, our commercial team is now delivering impressive sales results on our first two oncology drugs, ELUNATE\u00ae<\/sup> in metastatic colorectal cancer and the recently launched SULANDA\u00ae<\/sup> in neuroendocrine tumors. A New Drug Application was also submitted mid-last year for savolitinib in lung cancer and, subject to approval, it will be our third approved oncology drug and the first-in-class selective MET inhibitor on the market in China.\u201d<\/p>\n

\u201cOutside China, our fast expanding international organization, led mainly from the U.S., is developing five un-partnered oncology drug candidates. In 2020, it achieved three U.S. Food and Drug Administration fast track designations and initiated the rolling submission of surufatinib, our first U.S. New Drug Application filing.\u201d\u00a0\u00a0<\/p>\n

\u201cOver the next three years, we will continue to grow our R&D and commercial organizations globally to support the anticipated launch of our oncology drugs in China, the U.S. and Europe.\u201d<\/p>\n

\n I. COMMERCIAL OPERATIONS<\/strong>\n <\/p>\n